In our last episode, we laid the groundwork for managing brain metastases. Today, we tackle one of the most significant paradigm shifts in modern radiation oncology: the move away from routine whole-brain radiotherapy for patients with a limited number of brain metastases. For decades, WBRT was the standard. Now, for many patients, it's an inferior option. We will walk through the chronological story of the landmark trials that drove this revolution, culminating in the definitive evidence that establishes stereotactic radiosurgery, or SRS, alone as the standard of care for preserving cognitive function.